View all cases
UPC APP 17291/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Case details
- Status—ActionProcedural applicationCategoryOther Procedural
- Parties
- Claimants
- Sanofi SA
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Reps: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)Respondents- Accord Healthcare S.L.U.
- Accord Healthcare GmbH (AT)
- Accord Healthcare B.V.
- Accord Healthcare GmbH (DE)
- Accord Healthcare Italia Srl
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare AB
- STADA Nordic ApS
Reps: Jules Fabre (Pinsent Mason); Arjan Reijns (Pinsent Mason); Louise Millot (Pinsent Mason) - Division
- Munich LD
- Judges
- Matthias Zigann · Presiding judge and judge-rapporteur
- Technology
- Pharmaceutical & Medical
- Language
- —
- First decided
- May 8, 2025
Decisions
- 2025-05-08Generic application
Lengthy procedural order from Munich Local Division in consolidated infringement proceedings by Sanofi entities against multiple generic pharmaceutical companies (Accord, STADA, Dr. Reddy's, Zentiva) concerning EP 2 493 466 (insulin glargine). The order (judge-rapporteur Zigann) addresses numerous procedural matters including damages assessment timing, stay pending EPO Board of Appeal proceedings, and schedule for further pleadings. No substantive ruling; oral hearing deferred to await EPO BoA outcome.
Legal issues:Insulin glargine biosimilar infringementStay pending EPO Board of AppealCalculation of damages in pharmaceutical infringementCounterclaims for revocation
Documents
- A4825AC715439669D057A6EAB2C73859_en.pdf2025-05-08ENGLISH